These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 29693023)

  • 21. Donor-specific antibodies after ceasing immunosuppressive therapy, with or without an allograft nephrectomy.
    Del Bello A; Congy-Jolivet N; Sallusto F; Guilbeau-Frugier C; Cardeau-Desangles I; Fort M; Esposito L; Guitard J; Cointault O; Lavayssière L; Nogier MB; Blancher A; Rostaing L; Kamar N
    Clin J Am Soc Nephrol; 2012 Aug; 7(8):1310-9. PubMed ID: 22626959
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring of circulating antibodies in a renal transplantation population: preliminary results.
    Rodríguez Ferrero ML; Arroyo D; Panizo N; Vicario JL; Balas A; Anaya F
    Transplant Proc; 2012 Nov; 44(9):2548-50. PubMed ID: 23146450
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection.
    Gill JS; Landsberg D; Johnston O; Shapiro RJ; Magil AB; Wu V; Tinckam K; Keown P
    Transplantation; 2010 Jan; 89(2):178-84. PubMed ID: 20098280
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pretransplant serum BAFF levels are associated with pretransplant HLA immunization and renal allograft survival.
    Friebus-Kardash J; Wilde B; Keles D; Heinold A; Kribben A; Witzke O; Heinemann FM; Eisenberger U
    Transpl Immunol; 2018 Apr; 47():10-17. PubMed ID: 29277566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
    Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HLA Class II Antibodies at the Time of Kidney Transplantation and Cardiovascular Outcome: A Retrospective Cohort Study.
    Malfait T; Emonds MP; Daniëls L; Nagler EV; Van Biesen W; Van Laecke S
    Transplantation; 2020 Apr; 104(4):823-834. PubMed ID: 31369517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The role of HLA-specific antibodies in kidney transplant rejection: published studies and local data.
    Worthington JE; Martin S; Barker AJ; McWilliam LJ; Dyer PA
    Clin Transpl; 2006; ():349-61. PubMed ID: 18365389
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Allocation to highly sensitized patients based on acceptable mismatches results in low rejection rates comparable to nonsensitized patients.
    Heidt S; Haasnoot GW; Witvliet MD; van der Linden-van Oevelen MJH; Kamburova EG; Wisse BW; Joosten I; Allebes WA; van der Meer A; Hilbrands LB; Baas MC; Spierings E; Hack CE; van Reekum FE; van Zuilen AD; Verhaar MC; Bots ML; Drop ACAD; Plaisier L; Seelen MAJ; Sanders JS; Hepkema BG; Lambeck AJA; Bungener LB; Roozendaal C; Tilanus MGJ; Voorter CE; Wieten L; van Duijnhoven EM; Gelens MACJ; Christiaans MHL; van Ittersum FJ; Nurmohamed SA; Lardy NM; Swelsen W; van der Pant KAMI; van der Weerd NC; Ten Berge IJM; Bemelman FJ; Hoitsma A; van der Boog PJM; de Fijter JW; Betjes MGH; Otten HG; Roelen DL; Claas FHJ
    Am J Transplant; 2019 Oct; 19(10):2926-2933. PubMed ID: 31155833
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kidney allocation based on proven acceptable antigens results in superior graft survival in highly sensitized patients.
    Heidt S; Haasnoot GW; van Rood JJ; Witvliet MD; Claas FHJ
    Kidney Int; 2018 Feb; 93(2):491-500. PubMed ID: 28947279
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Specific "intra-allele" and "intra-broad antigen" human leukocyte antigen alloantibodies in kidney graft transplantation.
    Muro M; González-Soriano MJ; Salgado G; López R; Boix F; López M; Campillo JA; Martínez P; Botella C; Gimeno L; Minguela A; Alvarez-López MR; Llorente S
    Hum Immunol; 2010 Sep; 71(9):857-60. PubMed ID: 20510320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term impact of human leukocyte antigen mismatches combined with expanded criteria donor on allograft outcomes in deceased donor kidney transplantation.
    Shin S; Kim YH; Choi BH; Choi JY; Jung JH; Cho HK; Han DJ
    Clin Transplant; 2015 Jan; 29(1):44-51. PubMed ID: 25382387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
    Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
    Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HLA and lung transplantation.
    Ju L; Suberbielle C; Li X; Mooney N; Charron D
    Front Med; 2019 Jun; 13(3):298-313. PubMed ID: 29974325
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shared alloimmune responses against blood and transplant donors result in adverse clinical outcomes following blood transfusion post-renal transplantation.
    Hassan S; Regan F; Brown C; Harmer A; Anderson N; Beckwith H; Roufosse CA; Santos-Nunez E; Brookes P; Taube D; Willicombe M
    Am J Transplant; 2019 Jun; 19(6):1720-1729. PubMed ID: 30582278
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Humoral responses directed against non-human leukocyte antigens in solid-organ transplantation.
    Dragun D
    Transplantation; 2008 Oct; 86(8):1019-25. PubMed ID: 18946337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 2012 annual literature review of donor-specific HLA antibodies after organ transplantation.
    Kaneku H
    Clin Transpl; 2012; ():207-17. PubMed ID: 23721024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Posttransplant peripheral blood donor-specific interferon-γ enzyme-linked immune spot assay differentiates risk of subclinical rejection and de novo donor-specific alloantibodies in kidney transplant recipients.
    Crespo E; Cravedi P; Martorell J; Luque S; Melilli E; Cruzado JM; Jarque M; Meneghini M; Manonelles A; Donadei C; Lloberas N; Gomà M; Grinyó JM; Heeger P; Bestard O
    Kidney Int; 2017 Jul; 92(1):201-213. PubMed ID: 28274484
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies.
    Wissing KM; Fomegné G; Broeders N; Ghisdal L; Hoang AD; Mikhalski D; Donckier V; Vereerstraeten P; Abramowicz D
    Transplantation; 2008 Feb; 85(3):411-6. PubMed ID: 18322434
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.